Pages that link to "Item:Q3303813"
From MaRDI portal
The following pages link to On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial (Q3303813):
Displaying 22 items.
- Covariate-adjusted cost-effectiveness ratios (Q1298966) (← links)
- Covariate-adjusted Fisher randomization tests for the average treatment effect (Q2236896) (← links)
- Landmark estimation of survival and treatment effects in observational studies (Q2356620) (← links)
- Analysis of covariance with pre-treatment measurements in randomized trials: Comparison of equal and unequal slopes (Q3100764) (← links)
- A point estimator of the probability difference of overall treatment effect–simulation study (Q3118009) (← links)
- Analysis of Covariance in Parallel-Group Clinical Trials with Pretreatment Baselines (Q3201543) (← links)
- Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates (Q3530087) (← links)
- Estimation of Treatment Difference and Standard Deviation with Blinded Data in Clinical Trials (Q5122357) (← links)
- Robust Alternatives to ANCOVA for Estimating the Treatment Effect via a Randomized Comparative Study (Q5208089) (← links)
- (Q5263435) (← links)
- Comparing the performance of statistical methods that generalize effect estimates from randomized controlled trials to much larger target populations (Q5867468) (← links)
- Comparison of covariate balance weighting methods in estimating treatment effects (Q6052522) (← links)
- Developing and evaluating risk prediction models with panel current status data (Q6074506) (← links)
- Discussion of “Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes” (Q6079298) (← links)
- Rejoinder: Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes (Q6079300) (← links)
- Robust Approach to Combining Multiple Markers to Improve Surrogacy (Q6079767) (← links)
- Toward Better Practice of Covariate Adjustment in Analyzing Randomized Clinical Trials (Q6144753) (← links)
- Optimizing treatment allocation in randomized clinical trials by leveraging baseline covariates (Q6589218) (← links)
- Machine learning methods for leveraging baseline covariate information to improve the efficiency of clinical trials (Q6625579) (← links)
- Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study (Q6625704) (← links)
- Quantifying the feasibility of shortening clinical trial duration using surrogate markers (Q6628174) (← links)
- Sample size calculation for the augmented logrank test in randomized clinical trials (Q6628399) (← links)
